NCT03216343 is a Phase 1 clinical trial of Chiauranib in Small Cell Lung Cancer, sponsored by Chipscreen Biosciences, Ltd..

Who is sponsoring NCT03216343?

NCT03216343 is sponsored by Chipscreen Biosciences, Ltd..

What drugs are being tested in NCT03216343?

Interventions in NCT03216343: Chiauranib.

What condition does NCT03216343 study?

NCT03216343 studies Small Cell Lung Cancer.

Is NCT03216343 still recruiting?

NCT03216343 is currently completed. Last updated 30 August 2023.

Last reviewed 2023-08-30 · How we verify

NCT03216343

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

Completed Phase 1 Last updated 30 August 2023

What this trial tests

Phase 1 trial testing Chiauranib in Small Cell Lung Cancer in 48 participants. Completed in 15 May 2023.

Timeline

9 November 2017

Primary endpoint
4 November 2022

15 May 2023

Quick facts

Lead sponsor	Chipscreen Biosciences, Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	9 November 2017
Primary completion	4 November 2022
Estimated completion	15 May 2023
Sites	1 location across China

Drugs / interventions tested

Chiauranib — full drug profile →

Conditions studied

Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →

Sponsor

Chipscreen Biosciences, Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Tumor Microenvironment for Cancer Therapy.
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. · · 2019 · cited 865× · PMID 30781344 · DOI 10.3390/ijms20040840
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y, Tang F, Wei YQ, Wei XW. · · 2022 · cited 386× · PMID 35585567 · DOI 10.1186/s13045-022-01282-8
The two sides of chromosomal instability: drivers and brakes in cancer.
Hosea R, Hillary S, Naqvi S, Wu S, et al · · 2024 · cited 102× · PMID 38553459 · DOI 10.1038/s41392-024-01767-7
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.
Sen T, Gay CM, Byers LA. · · 2018 · cited 95× · PMID 29535912 · DOI 10.21037/tlcr.2018.02.03
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.
Dammert MA, Brägelmann J, Olsen RR, Böhm S, et al · · 2019 · cited 68× · PMID 31375684 · DOI 10.1038/s41467-019-11371-x
Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer.
Schulze AB, Evers G, Kerkhoff A, Mohr M, et al · · 2019 · cited 57× · PMID 31108964 · DOI 10.3390/cancers11050690
Second-Generation Antimitotics in Cancer Clinical Trials.
Novais P, Silva PMA, Amorim I, Bousbaa H. · · 2021 · cited 37× · PMID 34371703 · DOI 10.3390/pharmaceutics13071011
Aurora B Inhibitors as Cancer Therapeutics.
Kovacs AH, Zhao D, Hou J. · · 2023 · cited 32× · PMID 37110619 · DOI 10.3390/molecules28083385

Verify or expand the search:

Other trials of Chiauranib

Trials testing the same drug.

NCT07445295 — Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenoca · Phase 3 · not yet recruiting
NCT06492915 — Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma · Phase 2 · active not recruiting
NCT05497843 — Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) · Phase 2 · completed
NCT05371899 — Mass Balance Study of [14C]Chiauranib · NA · completed
NCT05346601 — Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Other Chipscreen Biosciences, Ltd. trials

Trials by the same sponsor.

NCT07511010 — Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets · Phase 1 · not yet recruiting
NCT07519265 — Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
NCT07412015 — Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets · NA · not yet recruiting
NCT07445295 — Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenoca · Phase 3 · not yet recruiting
NCT07129382 — A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03216343 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chipscreen Biosciences, Ltd.
Last refreshed: 30 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03216343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing